Glenmark Life Sciences: growth was driven by strong momentum in the Generic API business
Glenmark Life Sciences: growth was driven by strong momentum in the Generic API business
- Net Cash Generated from Operating Activities: 313 cr Vs 597
- EPS: 38 Vs 36
- Revenue: 2190 vs 2138
- PAT: 470 Vs 419
- EBITDA margins were at 31.1%, Vs 29.7%
- Capital expenditure for FY23 was at Rs. 1702 Mn
- R&D expenditure 3.0% of sales
- ROICE was 33.5% for FY23
- The growth was driven by strong momentum in the Generic API business as well as significant recovery in demand in the CDMO business
- cash generation remains strong during FY23 leading to stable debt free balance sheet with healthy cash
- Capex update
- Dahej: o The brownfield expansion for the Generic API products at Dahej facility is complete with 240 KL capacity. o The brownfield expansion at Dahej for the Oncology plant is completed.
- Ankleshwar: o Intermediate manufacturing block at the Ankleshwar site with a manufacturing capacity of 400 KL, of which 192 KL is commissioned and operational and balance 208KL will be operational in second half of FY24.
- Solapur: o The Company has received Environmental Clearance for the installation of 1000 KL capacity along with CTE (Consent to Establish) for the planned greenfield site and construction work will begin in FY24.
Comments
Post a Comment